MedTrace Logo

Hemoadsorption for Severe Ischemic Stroke

NCT07127484 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2026-05-15

No results posted yet for this study

Summary

This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke

Conditions

Interventions

PROCEDURE

Hemoadsorption

Patients in intervention group will receive standard treatment plus hemoadsorption therapy administered once on days 1, 3, and 5 following enrollment.

Sponsors & Collaborators

  • Anqing Municipal Hospital

    collaborator OTHER

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Gansu Provincial Central Hospital

    collaborator UNKNOWN

  • Baotou Central Hospital

    collaborator OTHER

  • The NO.1 People's Hospital of Shizuishan

    collaborator UNKNOWN

  • Fuyang people's hospital

    collaborator OTHER

  • Second People's Hospital of Hefei City

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • THE SECOND PEOPLE'S HOSPITAL, WUHU

    collaborator UNKNOWN

  • First Affiliated Hospital of Wannan Medical College

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2027-01-31
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07127484 on ClinicalTrials.gov